Publicacions
-
Fernandez-Sojo J, Horton R, Cid J, Azqueta C, Garcia-Buendia A, Valdivia E, Martorell L, Rubio-Lopez N, Codinach M, Aran G, Marsal-Ricoma J, Mussetti A, Martino R, Diaz-de-Heredia C, Ferra C, Valcarcel D, Linares M, Ancochea A, Garcia-Rey E, García-Muñoz N, Medina L, Carreras E, Villa J, Lozano M, Gibson D and Querol S.
Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry
BONE MARROW TRANSPLANTATION . 57(10): 1531-1538. Nº de cites: 5
-
Solsona M, Berrueco R, Sebastián E, Cervera A, Sastre A, Astigarraga I, Argilés B, Dasí MA, Dapena JL and Monteagudo E.
Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY . 88(9): 4220-4223.
-
Ortigoza-Escobar JD, Fernández de Sevilla-Estrach M, Monfort L, Anton-Lopez J, Iglesias-Jimenez E, Rebollo M, Del Prado-Sanchez C, Arostegui JI, Mensa-Vilaró A, Alsina L, Rodriguez-Vigil Iturrate C, Niemeyer CM, Jou-Munoz C and Català-Temprano A.
Cytokine profile and brain biopsy in a case of childhood-onset central nervous system vasculitis in Noonan syndrome-like disorder due to a novel CBL variant
JOURNAL OF NEUROIMMUNOLOGY . 369: 577917-577917. Nº de cites: 2
-
Ramos-Muntada M, Trincado JL, Blanco J, Bueno C, Rodríguez-Cortez VC, Bataller A, López-Millán B, Schwab C, Ortega M, Velasco P, Blanco ML, Nomdedeu J, Ramírez-Orellana M, Minguela A, Fuster JL, Cuatrecasas E, Camós-Guijosa M, Ballerini P, Escherich G, Boer J, denBoer M, Hernández-Rivas JM, Calasanz MJ, Cazzaniga G, Harrison CJ, Menéndez P and Molina O.
Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
MOLECULAR ONCOLOGY . 16(16): 2899-2919. Nº de cites: 5
-
Megías-Vericat JE, Bonanad Boix S, Berrueco R, Mingot-Castellano ME, Rodríguez López M, Canaro Hirnyk M, Mateo Arranz J, Calvo Villas JM, Haya Guaita S, Mesegue-Meda M, López Jaime F, Albo-López C, Palomero-Massanet A, Vilalta Seto N, Leciñena IL, Haro ARC and Poveda Andrés JL.
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
THROMBOSIS RESEARCH . 216: 35-42. Nº de cites: 4
-
Kobialka P, Sabata H, Vilalta O, Gouveia L, Angulo-Urarte A, Muixí L, Zanoncello J, Muñoz-Aznar O, Gene-Olaciregui N, Fanlo L, Esteve-Codina A, Lavarino C, Javierre BM, Celis-Passini V, Rovira-Zurriaga C, López-Fernández S, Baselga E, Mora J, Castillo SD and Graupera M.
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib
EMBO Molecular Medicine . 14(7): . Nº de cites: 25
-
Bueno C, Barrena S, Bataller A, Ortiz-Maldonado V, Elliott N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, Gonzalez M, Morgades M, Sorigué M, Barcena P, Zanetti SR, Torrebadell-Burriel M, Vega-García N, Rives-Solà S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan-Otero M, Delgado J, Urbano-Ispizua Á, Ribera JM, Orfao A, Roy A and Menéndez P.
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
Blood . 140(1): 38-44. Nº de cites: 17
-
García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz-Aznar O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C.
MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment
BMC Cancer . 22(1): 669-669. Nº de cites: 8
-
Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives-Solà S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F and Zwaan CM.
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Leukemia . 36(6): 1516-1524. Nº de cites: 27
-
Laetsch TW, Maude SL, Balduzzi A, Rives-Solà S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R and Grupp SA.
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia
Leukemia . 36(6): 1508-1515. Nº de cites: 20